Change in number of shares and votes in Moberg Pharma

STOCKHOLM, Sweden--()--Regulatory News:

The number of shares and votes in Moberg Pharma AB (publ) has increased by 71,666 to 14,289,188 during June 2016. Therefore, there are in total 14,289,188 shares and votes in the company as of June 30, 2016.

The reason for the increase is that warrants in Moberg Pharma have been exercised under the company’s share-based incentive program.

About this information               

Moberg Pharma discloses this information pursuant to the Swedish Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 8.30 a.m. (CET) on June 30, 2016.

About Moberg Pharma, www.mobergpharma.com Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 40 countries. The company’s portfolio includes the OTC brands Kerasal®, Kerasal Nail®, Balmex®, Domeboro®. Kerasal Nail®(Emtrix®or Nalox™ in certain markets) is a leading OTC treatment of nail disorders in the U.S., Canada and several EU markets and is currently being launched in Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focuses on innovative drug delivery of proven compounds and include two clinical stage assets, MOB-015 (onychomycosis) and BUPI (pain management in oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).

This information was brought to you by Cision http://news.cision.com

Contacts

For additional information contact:
Peter Wolpert, CEO, Telephone: +46 (0)70 - 735 7135,
E-mail: peter.wolpert@mobergpharma.se
or
Anna Ljung, CFO, Telephone: +46 (0)70 - 766 60 30,
E-mail: anna.ljung@mobergpharma.se

Contacts

For additional information contact:
Peter Wolpert, CEO, Telephone: +46 (0)70 - 735 7135,
E-mail: peter.wolpert@mobergpharma.se
or
Anna Ljung, CFO, Telephone: +46 (0)70 - 766 60 30,
E-mail: anna.ljung@mobergpharma.se